Silexion Therapeutics Corp (SLXN) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Silexion Therapeutics Corp (SLXN) closed at USD 0.17 on 2026-10-14, a change of -99.5 % over the past year, with a market capitalization of USD 2.74M.

Silexion Therapeutics Corp recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Silexion Therapeutics Corp key figures

Previous close

USD 0.17 (2026-10-14)

1-year change

-99.5 %

Market cap

USD 2.74M

Enterprise value

USD 231,888

P/E ratio (trailing)

-0.01

P/E ratio (forward)

-0.30

EPS (trailing)

-27.21

EPS (forward)

-0.64

PEG ratio

n/a

Price to book

23.62

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.18

Employees

13

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Silexion Therapeutics Corp

Silexion Therapeutics Corp, a clinical-stage biotechnology company, discovers and develops RNA interference (RNAi) therapies for KRAS-driven cancers. Its products comprise SIL204 second-generation small interfering RNA (siRNA) undergoing phase 2/3 clinical evaluation for pancreatic cancer and silence mutant KRAS oncogene expression. The company was founded in 2008 and is headquartered in Ramat Gan, Israel.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Silexion Therapeutics Corp and compare it with other stocks.